Heartseed tests world’s first catheter-delivered stem cell therapy for heart failure (opens in new tab)

Heartseed, a Tokyo-based biotechnology company, dosed the first patient in its domestic Phase I/II EMERALD study of HS-005, an allogeneic iPSC-derived cardiomyocyte spheroid therapy delivered via endocardial catheter targeting severe heart failure caused by ischemic heart disease or dilated cardiomyopathy. The study marks the world’s first clinical trial to administer iPSC-derived cardiomyocyte spheroids by catheter. […] The post appeared first on <a href="